No Prescription |
 |
 | ||
|
Imuran Azasan |
|
| ||
No Prescription » Prescription Drugs 9 » Imuran Azasan Azathioprine is used with other medications to prevent rejection of a kidney transplant. It works by weakening your body's defense system (immune system) to help your body accept the new kidney as if it were your own. This medication belongs to a class of drugs known as immunosuppressants.Azathioprine is also used to treat patients with severe rheumatoid arthritis who have not responded to other medications (e.g. nonsteroidal anti-inflammatory drugs/NSAIDs such as ibuprofen). Rheumatoid arthritis is thought to be caused by the immune system attacking the joints. Early treatment of rheumatoid arthritis with more aggressive therapy such as azathioprine helps to reduce further joint damage and to preserve joint function. Buy Imuran Azasan and other Prescription Drugs 9 products online at Medstore. Buy Online at Medstore - Click Here!
About Imuran Azasan: Product Type: Prescription Drugs 9 Imuran ( Azasan Generic Azathioprine ) Imuran (Azasan Generic Azathioprine) Azasan Generic Azathioprine 25mg 100 tablets 25mg 200 tablets 25mg 400 tablets 50mg 400 tablets 50mg 200 tablets 50mg 100 tablets Azasan Generic Azathioprine Imuran
View more Prescription Drugs 9 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
